Medicus company information, Employees & Contact Information

First UAE Patient Enrolled in Medicus' Trial for Non-Invasive BCC Therapy Dermatology Times

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing The Daily Jeffersonian

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin azcentral.com and The Arizona Republic

Medicus Pharma Announces $8M Non-Dilutive Debenture Financing citybiz

$6B Market Potential: Medicus Pharma Secures $8M Financing to Advance Novel Prostate Drug Teverelix Stock Titan

Medicus Pharma: High-Risk, But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment Seeking Alpha

Vaccination for prevention of hearing loss: a scoping review - Communications Medicine Nature

Medicus Moves Forward in UAE Trial for Novel, Non-Invasive BCC Therapy Dermatology Times

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) GlobeNewswire

Sam Hupert Buys Handful Of Shares In Pro Medicus simplywall.st

60% Clinical Clearance: Medicus Pharma's Novel Microneedle Array Shows Promise in Skin Cancer Treatment Stock Titan

Medicus Reports Promising Interim Results for Non-Invasive BCC Treatment Dermatology Times

Pro Medicus full-year profit surges 40pc on contract wins AFR

Pro Medicus (ASX: PME) FY 2025 Results Analysis: Record Results Meet High Expectations A Rich Life

Is The 4D Medical (ASX: 4DX) Share Price Overhyped? A Rich Life

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) Yahoo Finance

Medicus Pharma Submits Phase 2 IND Clinical Protocol to FDA to Non-Invasively Treat BCC Dermatology Times

MSPs Abacus Group, Medicus IT Merge Combining Health Care, Financial Services Muscle CRN Magazine

Evening Wrap: ASX 200 slumps as tech darling Pro Medicus tumbles, Woodside bolsters energy, gold powers ahead Market Index

Medicus Pharma stock target lifted to $27 on Antev acquisition Investing.com

Meet Australia’s biggest company you’ve never heard of The Australian

9 Outdated Things People Over 40 Should NEVER Have in Their Homes House Beautiful

DEFENSE WIN: Court Dismisses TCPA Class Action – Recruitment Calls Are Not “Telephone Solicitations” The National Law Review

Healthcare MSP M&A: Medicus IT Acquires MDcentric Technologies - ChannelE2E

On the Trail of an Elusive Organ-Trafficking Decision in Kosovo Balkan Insight

Pro Medicus’ billionaire boss says simplicity secret of success AFR

Pro Medicus CEO confident on competitors as dizzyingly expensive share price keeps rising Capital Brief

How Sam Hupert turned Pro Medicus into an understated giant AFR

Pro Medicus runs to $300 so fast investors can’t catch up AFR

Pro Medicus: A decade of exceptional growth and sustained performance roger montgomery

Evening Wrap: ASX 200 rallies as CSL, Telix and Pro Medicus lead healthcare sector rebound, small cap gold melt-up continues Market Index

Pro Medicus had a 63% annualised return over the last decade. What lessons can we take from this top performer? Morningstar Australia

No need to call the doctor as local GPs switch online Guernsey Press

Up 72% since April, Pro Medicus shares are jumping today on big US tariff news The Motley Fool Australia

Pro Medicus goes sky-high as it looks to the cloud AFR

ASX 200 Live Today - Monday, 29th September Market Index

The "Medicus" case leaves Kosovo without the Law on organ transplants Telegrafi

Kosovo Organ-Trafficking Defendants Deny Breaking Law Balkan Insight

Life Hits Hard, Four Costly Lessons from the Downfall of Medicus Research SupplySide Supplement Journal

Is it too late to buy Pro Medicus shares? The Motley Fool Australia

Kosovo Clinic ‘Removed Patients’ Kidneys Unnecessarily’ Balkan Insight

Pro Medicus shares: Bull vs. Bear The Motley Fool Australia

The Physician (2013) ⭐ 7.2 | Adventure, Drama, History IMDb

This ASX 200 med-tech stock has no debt, pays dividends and is growing at 30% per year! The Motley Fool Australia

Marty Might Not Testify in the Medicus Case Balkan Insight

Zero to Hero: How Pro Medicus became a $2.7bn ASX200 stock without raising a cent Stockhead

Physician recruiting firms agree to merge Modern Healthcare News

Medicus Pharma Ltd. (NASDAQ: MDCX): Advancing Non‑Invasive Oncology Therapies Small Cap Exclusive